A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less ...

Lilly is considering expanding the availability of lower-priced vials of its blockbuster obesity drug Zepbound ...

The biotech has named Jamie Coleman its chief commercial officer, per a Monday announcement, putting her in charge of the ...

This order relates to certain FDA-approved Mounjaro and Zepbound products. The Mounjaro products are pre-filled single-dose pens (2.5 mg/0.5 mL, 5 mg/0.5 mL, 7.5 mg/0.5 mL, 10 mg/0.5 mL ...

The newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ways they affect the body—both helpful and harmful—beyond reducing ...

Results from a separate trial that were released in 2022 showed patients taking a high dose of Lilly's (LLY.N), opens new tab Zepbound saw more than 20% weight loss. "The results give us greater ...